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CYTOKINE REMOVAL
Is cytokine removal by continuous hemofiltration feasible?
HEINZ-GU¨NTER SIEBERTH and HORST P. KIERDORF
Medical Clinic II, University of Technology Aachen, Aachen, Germany
Is cytokine removal by continuous hemofiltration feasible? Pa- bodies, soluble TNF-a receptors, and IL-1 receptor an-
tients who are critically ill with acute renal failure and sepsis tagonists in double-blind, placebo controlled trials [1–8].
have extremely high mortality rates. While it seems reasonable Although a small (2 to 3%) increase in the 28-day sur-that eliminating the inflammatory mediators (such as cytokines,
vival rate has been reported with anticytokine therapy,chemokines, tumor necrosis factor-a, etc.) by continuous renal
replacement therapy (CRRT) would be effective, studies show the effect is not statistically significant. In fact, increased
that only insubstantial numbers of these mediators are removed mortality has been reported by Fisher et al with the TNF
in comparison with endogenous clearance. Mass removal seems receptor Fc fusion protein [9].only to be effective when highly permeable membranes (sieving
Another method for treating these disease entities hascoefficient of approximately 1.0) are used, there is a filtrate
volume greater than 2 liters/hour, and when the half-life of the been to eliminate cytokines and chemokines instead of
substance to be eliminated is greater than 60 minutes. Removal blocking them. A considerable number of experimental
of cytokines by membrane adsorption is another possibility. and clinical investigators have reported employing hemo-However, because the membrane surfaces are saturated after
filtration, hemodiafiltration, plasmapheresis, and adsorp-a few hours, frequent filter changes are necessary for them to
tion to eliminate cytokines and chemokines in an attemptgenerate effective adsorption of these mediators. Despite filter
changes, only a brief and transient drop in the TNF plasma to reduce the high mortality of SIRS [10]. One may
level has been observed. Controlled clinical trials are needed assume that eliminating cytokines from the plasma can
to determine whether or not CRRT actually has a beneficial
only influence its endocrine, but not the autocrine oreffect on the systemic inflammatory response syndrome (SIRS).
paracrine mode of action.
A great number of supporting and hampering factors
RESULTS OF INFLAMMATORY MEDIATOR
are involved in the complex network that leads to sepsis.
REMOVAL BY HEMOFILTRATIONThese include cytokines, chemokines, adhesion mole-
Until now, there have been many hints, but no proof,cules, E-selectin, prostaglandins, and various phagocytic
that extracorporeal elimination of septic mediators in-cells of the immune system, the systemic inflammatory
fluences the course of the disease. No studies have beenresponse syndrome (SIRS) and the counter-regulatory
able to prove that the elimination of cytokines improvesanti-inflammatory response syndrome (CARS).
The inflammatory cytokines tumor necrosis factor-a the survival rate. Most of these studies have been carried
(TNF-a) and interleukin-1 (IL-1) cause the same spec- out on patients with acute renal failure. In a meta-ana-
trum of clinical symptoms as do staphylococcal exotoxin lytic study comparing intermittently hemodialyzed to
or gram-negative endotoxins. IL-6, IL-8, and platelet- continuously hemofiltrated patients, the last group ex-
activating factor are further important elements that stim- hibited an approximately 10% better survival rate. How-
ulate inflammation. Extensive experimental and clinical ever, proof that this improvement was a result of media-
investigations are now being focused on the concept of tor elimination does not exist (abstract; Simpson et al,
blocking the biological properties of IL-1 and TNF. Block- Nephrol Dial Transplant 8:946, 1993) [11–17]. Other
ing IL-1 or TNF-a has been highly successful in patients studies have shown that partial respiratory, circulatory,
with rheumatoid arthritis, inflammatory bowel disease, or and metabolic failure can be beneficially influenced by
graft-versus-host reaction. However, despite positive ex- continuous hemofiltration. Again, the possibility that this
perience with animal models, anticytokine therapy for sep- benefit is attributable to the elimination of cytokines has
sis has been disappointing. Over 13,000 patients with septic
been discussed, but not proven [18–21].
shock have entered trials with TNF-a–neutralizing anti-
The few controlled studies on patients without renal
insufficiency, in which the influence of hemofiltration has
Key words: sepsis, SIRS, acute renal failure, cytokines, mass transfer. been investigated, have not clearly shown that mediator
elimination positively effects the course of the disease 1999 by the International Society of Nephrology
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Table 2. Efficacy of blood purificationTable 1. Extracorporeal mass removal
(mass removal during endogenous half-life)
Extracorporeal mass removal (EM) 5
mtot 5 (mi 2 mo) · t21 Filtered and adsorbed mass
Endogenous half-life
(ng)mi 5 Ci · P · t21
mo 5 Co · (p – F) · t21
Endogenous clearance (half-life) (EC) 5mh 5 mtot · half-life21 Distribution volume · Serum concentration
2
(ng)mf 5 Cf · F · half-life21
ma 5 mtot 2 mf
P 5 B · (1 2 Qi) Efficacy of blood purification (EB) 5
EM · 100
EC
(%)
mtot 5 total mass removal · time21
mi 5 incoming mass · time21
mo 5 outgoing mass · time21
mh 5 mass removal · half-life21
mf 5 mass removal by filtration · half-life21
ma 5 mass removal by adsorption · half-life21 sepsis or SIRS-related factors can influence the course
B 5 blood flow ml/60 min of the disease. It is also possible that removal of isolated
P 5 plasma flow ml/60 min
mediators after a prolonged course of the disease is noF 5 filtrate volume ml/60 min
Qi 5 hematocrit inflow longer beneficial.
Ci 5 serum concentration inflow According to Fong et al, “Hence, the entire milieu of
Co 5 serum concentration outflow hormonal and cytokine mediators must be considered inCf 5 filtrate concentration
the assessment of postinjury biologic response” [40].
CALCULATING THE MASS REMOVAL
[22–25]. Even studies in hemofiltrated patients with im- OF CYTOKINES
proving circulatory conditions or in patients receiving
To judge the quality of an elimination process, it is
less catecholamine support could not show that mediator
necessary to determine not only a concentration differ-
elimination positively influenced the course of the dis-
ence but the total amount eliminated (mass removal).
ease [26, 27].
The appropriate measurements are shown in Table 1.In animal models, the survival length and rate after
Because cytokines occur in different fluids, internal stan-exposure to exotoxins and endotoxins can be improved
dards should be contained in those fluids under investiga-by the early initiation of hemofiltration [28–31], and infu-
tion. It should be kept in mind that values attained withsion of the filtrate can induce septic symptoms in healthy
an enzyme-linked immunosorbent assay (ELISA) mayanimals. However, it has not been proven that these symp-
not be the same as those achieved with a bioassay. Thistoms are caused by mediators, as it is possible that filtered
is particularly true for TNF-a, which is inactive in theexotoxins may induce the septic symptoms [32]. Hemo-
monomeric form but active in the trimeric form.filtration has shown no beneficial effect in animal models
Before judging the efficiency of a procedure, thein which an infection such as peritonitis, instead of exo-
amount of a substance eliminated extracorporeally musttoxins or indotoxins, was employed to induce sepsis [33].
be established in relationship to the endogenous clear-A series of investigations has shown that hemofiltra-
ance (Table 2).tion does remove cytokines from the circulation by con-
Aside from the parameters listed in Table 1, the fol-vection [20, 21, 34–39]. Commonly, removal is expressed
lowing parameters are necessary for a calculation: molec-as a percentage of the blood or plasma concentration,
ular weight [41], sieving coefficient in vivo [10, 20, 21,and not as a portion of the total body amount or with
37–39, 42], virtual distribution volume in the body [43],respect to the metabolic clearance rate.
and internal elimination rate (half-life) [40, 43–50].
These reference data are listed in Table 3. Considering
CONDITIONS FOR SUCCESSFUL their molecular weights, a higher sieving coefficient could
MEDIATOR ELIMINATION be expected for most of the cytokines. However, binding
to circulating receptors or other proteins and secondaryEffective blood purification, and also in the case of
membrane formation in the hemofilters result in a de-mediators, generally takes place under three conditions:
crease in the sieving coefficient. That may be one reason(a) The extracorporeally eliminated amount must be of
why the coefficients vary considerably between investiga-consequence when regarding the total body amount. (b)
tors, between different membrane types, and are notWith respect to the endogenous clearance rate, the extra-
constant during the course of filtration. However, be-corporeal clearance rate must be so high that (c) the
cause of the short metabolic half-life, this variability is ofamount eliminated extracorporeally beneficially influ-
little significance when purifying the blood of cytokines.ences the course of the disease.
It is not clear whether or not the elimination of isolated The distribution volume of cytokines with a molecular
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Table 3. Molecular weight, sieving coefficients and endogenous half-lives of some cytokines
Molecular
Cytokines weight Sieving coefficient Half-life minutes
TNFa ,17.4 0–0.2,a 0.01–1.0 [52] ,6–7 [45] ,14–17 [43]
monomer ,15 [47]
trimer ,52
IL-1 ,18 0.07–0.42,b 0.35 [38] ,6–10 [44]
0.18 [39], 0.12–1.0 [52]
IL-2 ,6–10 [46]
IL-6 ,26 0.01–0.32 [52] ,6 [49]
IL-8 ,6–8 0.0–0.48,b 0.44 [39]
a Data are from the literature [10]
b Rising sieving coefficient during hemofiltration
Table 4. Mass removal by hemofiltration (%) in relation to the with different filtrate volumes and sieving coefficients is
endogenous half-life and dependence of filtrate volume and the
calculated. The calculation with higher sieving coeffi-sieving coefficient
cients demonstrates the mass transfer that can occur with
Half-life of mediator,
membrane improvement. Because no data are available100% endogenously removed
Filtrate Sieving about the half-life of mediators in patients with sepsisvolume coefficient 15 min 30 min 60 min 120 min
or SIRS, the calculations are carried out with half-lives
1 liter/hr 0.1 0.3 0.6 1.2 2.4
of up to 120 minutes.1 liter/hr 0.25 1 2 4 8
1 liter/hr 0.5 2 4 8 16
1 liter/hr 1 4 8 16 32
2 liter/hr 0.1 0.6 1.2 2.4 4.8 DISCUSSION2 liter/hr 0.25 2 4 8 16
2 liter/hr 0.5 4 8 16 32 The question of whether continual renal replacement
2 liter/hr 1.0 8 16 32 64
therapy (CRRT) has a beneficial effect on sepsis or SIRS
can be clarified only in controlled studies. Whether or
not substantial amounts of various mediators can be re-
moved by hemofiltration must be established by mea-weight below 20 kDa should correspond to at least the
extracorporeal space, which entails approximately 15% surement.
of the body weight. Determination of the half-life of the The results presented here with relevant data show
cytokines raises some problems. It is possible to estimate that hemofiltration can only remove insubstantial
the half-life after one dose of a labeled cytokine [49] or amounts of mediators, representing only a few percent-
by the slope of the curve after a single application of an ages, compared with endogenous clearance. In concur-
exotoxin or endotoxin. However, continuous formation rence, most investigators have reported no (abstract;
of cytokines must be considered [47]. No reference data Kierdorf et al, Ren Fail 14:98, 1992) [27, 42] or only
are available for the half-life of cytokines in patients minimal decreases in the plasma mediator concentration
with SIRS, where increased formation occurs. [51], even when employing hemofiltration over several
For the subsequent calculations, a half-life for TNF-a days. An effective mass removal is only possible with a
of 15 minutes has been employed, which corresponds to highly permeable membrane (sieving coefficient approx-
the half-life of other cytokines. An extracellular space imately 1.0), a high filtrate volume ($2 liter/hr), and
of 15 liters and a filtration volume of 1 liter/hr and a
when the half-life of the substance to be eliminated is
relatively high sieving coefficient for TNF-a of 0.25 are
greater than 60 minutes.assumed. With a plasma TNF-a concentration of 500
Membrane adsorption has not been taken into accountpg/ml or 500 ng/liter and an extracellular volume of 15
in these calculations. Adsorption onto the majority ofliters, a total amount of approximately 7500 ng TNF-a
membranes generally in use is low and only for poly-is calculated. During the 15-minute half-life, roughly
acrylonitrile membranes relatively high [52]. However,3750 ng are metabolized while at the same time, 250 ml
within a few hours, the adsorption on the membranefiltrate with approximately 30 ng TNF-a is removed.
surface is saturated. Frequent filter change or developingComparing the metabolized amount of TNF-a and the
special filters might generate more efficient adsorption,amount removed by hemofiltration, a mass transfer by
perhaps with better mass removal of mediators encoun-hemofiltration of only approximately 1% occurs. In-
tered during sepsis, but even during treatment with thiscreasing the sieving coefficient to 1 increases the amount
type of membrane, only a short transient drop of theremoved by hemofiltration to approximately 4%.
In Table 4, the mass removal of a single mediator TNF plasma level could be observed.
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W: Acute renal failure in abdominal infection: Comparison ofCONCLUSION
hemodialysis and continuous arteriovenous hemofiltration. Anasth
Following disappointing results of treating sepsis or Intensivther Notfallmed 21:212–217, 1986
13. Alarabi AA, Danielson BG, Wikstrom B, Wahlberg J: OutcomeSIRS with antibodies and receptor blockers for cyto-
of continuous arteriovenous hemofiltration (CAVH) in one centre.kines, hope had been invested in removing these sub- Ups J Med Sci 94:299–303, 1989
stances by blood purification. The calculations presented 14. Brian R, McDonald BR, Metha RL: Decreased mortality in
patients with acute renal failure undergoing continuous arteriove-here show that continuous hemofiltration can remove
nous hemodialysis. Contrib Nephrol 93:51–56, 1991only insubstantial amounts of mediators when compared 15. Bellomo R, Mansfield D, Rumble S, Shapiro J, Parkin G, Boyce
with endogenous clearance. This does not mean that N: Acute renal failure in critical illness: Conventional dialysis ver-
sus acute continuous hemodiafiltration. ASAIO J 38:654–657, 1992continuous renal replacement therapy (CRRT) cannot
16. Bellomo R, Boyce N: Continuous venovenous hemodiafiltrationpositively influence sepsis or SIRS in other ways. compared with conventional dialysis in critically ill patients with
acute renal failure. ASAIO J 30:794–797, 1993Reprint requests to Dr. Heinz-Gu¨nter Sieberth, Medical Klinik II, 17. Kruczynski K, Irvine-Bird K, Toffelmire EB, Morton AR: AUniversita¨tsklinikum, Pauwelsstrasse 30, D52074 Aachen, Germany. comparison of continuous arteriovenous hemofiltration and inter-
mittent hemodialysis in acute renal failure patients in the intensive
care unit. ASAIO J 39:778–781, 1993REFERENCES
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